ATG Biotechnology
Pioneering enzyme gene modification and advanced protein engineering to enhance life science research, in vitro diagnostics, and biomedicine.
Pioneering enzyme gene modification and advanced protein engineering to enhance life science research, in vitro diagnostics, and biomedicine.
ATG Biotechnology, founded in 2018, is a pioneering company in the biopharma and biotechnology industries. Their slogan, "Pioneering enzyme gene modification and advanced protein engineering to enhance life science research, in vitro diagnostics, and biomedicine," encapsulates their commitment to cutting-edge technologies.
ATG Biotechnology, operating under the name Jujiang Bio, focuses on upstream technologies such as enzyme gene modification, advanced protein engineering, and large-scale protein fermentation post-processing technology. Their innovative product technology holds significance in various sectors including life science research, in vitro diagnostics, biomedicine, and other business areas.
The most recent milestone for ATG Biotechnology is their Series A investment received on 22 May 2023, with the renowned CITIC Capital as the leading investor. This investment is a testament to the potential and innovation of ATG Biotechnology, further solidifying their position as a key player in the biotechnology sector.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | Unknown | 1 |
|
22 May 2023 |
| Angel Round | Unknown | 1 | Dynamic Balance Capital | 18 Oct 2021 |
No recent news or press coverage available for ATG Biotechnology.
We care about your data, and we'd love to use cookies make your experience better.